What Is Dyskinesia?
Feb 22, 2022
Contact: Audrey Hu audrey.hu@wecistanche.com
Parkinson's disease is a common neurodegenerative disease. Dopaminergic drug replacement therapy can significantly improve the motor symptoms of patients with Parkinson's disease. It is the core drug for Parkinson's disease treatment. Dopaminergic drugs can lead to motor complications in Parkinson's disease. Motor complications can be divided into two categories: motor fluctuations and dyskinesia.
Anti-Parkinson's disease: herb cistanche
1. Motion fluctuations
Motor fluctuations can be further subdivided into diminished efficacy, end-of-dose deterioration, switching phenomena, and freezing phenomena. Dyskinesia is a serious type of motor complication of Parkinson's disease, with involuntary movements as the main clinical feature, often manifested as episodic, irregular chorea-like, dystonic-like movements, of which the limbs and trunk are more involved See.
2. Dyskinesia
Dyskinesias can be subdivided into dose peak dyskinesia, bidirectional dyskinesia, and dystonia. Because dyskinesia can affect the stability of patients' walking and standing, it brings a lot of inconvenience to patients' daily life and work, and even falls.
Causation of dyskinesia
The pathogenic mechanism of dyskinesia is still unclear. The latest research shows that the occurrence of dyskinesia is related to a variety of risk factors, which can be divided into uncontrollable factors and controllable factors. Uncontrollable factors are related to the disease itself, and are affected by the age of onset, gender, disease course, disease severity, and type of the patient; controllable factors are related to treatment and are related to the timing of starting drug treatment, the type of drug, the dose of levodopa and the time of treatment. process and concentration fluctuations. Foreign reports after 4 to 6 years of treatment, the incidence of levodopa-induced dyskinesia is close to 40%. Levodopa-induced dyskinesia often corresponds to the time of peak plasma levodopa concentration and disappears with decreasing levodopa dose. Younger age of onset is a major risk factor for levodopa-induced dyskinesia, so we advocate delaying the use of levodopa and limiting the dose of levodopa in young patients to reduce the risk of dyskinesia.
Treatment of dyskinesia
At present, there are mainly the following methods for the treatment of dyskinesia: 1. Adjusting the dose of levodopa, using small doses of levodopa multiple times and fractionated treatment can help reduce peak dose dyskinesia. 2. Adding amantadine, potential side effects are sedation, hallucinations, confusion, foot edema, myoclonus, livedo reticularis and corneal edema. 3. Adding the atypical antipsychotic drug clozapine, potential side effects are agranulocytosis, salivation, somnolence, seizures, orthostatic hypotension and myocarditis. 4. For patients with severe dyskinesia and difficulty to improve by adjusting drugs, implantation of a brain pacemaker can achieve satisfactory results, but economic conditions are required. In addition, quetiapine, safinamide, istraphylline, etoprazine, etc. have also been applied in clinical, but the efficacy remains to be discussed.
In addition, the traditional Chinese herbal medicine Cistanche also has a good preventive and therapeutic effect on Parkinson's disease. As a plant that is both food and herb. Cistanche deserticola contains a lot of phenylethanoid glycosides, flavonoids, polysaccharides, alkaloids and terpenoids. Modern pharmacological studies have confirmed that regular consumption of Cistanche can effectively reduce brain damage and cell apoptosis, and can effectively combat Alzheimer's disease and Parkinson's disease.
